Boston Scientific Corporation (NYSE:BSX) is Cavalier Investments LLC's 9th Largest Position

Cavalier Investments LLC lowered its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 41.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,838 shares of the medical equipment provider's stock after selling 74,593 shares during the quarter. Boston Scientific makes up approximately 3.6% of Cavalier Investments LLC's holdings, making the stock its 9th biggest position. Cavalier Investments LLC's holdings in Boston Scientific were worth $10,475,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BSX. Colonial Trust Co SC raised its stake in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares in the last quarter. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $25,000. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific in the fourth quarter worth $26,000. Ameriflex Group Inc. bought a new stake in shares of Boston Scientific during the 4th quarter worth $31,000. Finally, Fairway Wealth LLC acquired a new position in Boston Scientific in the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the transaction, the executive vice president now directly owns 178,342 shares of the company's stock, valued at approximately $18,347,824.96. The trade was a 24.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 411,970 shares of company stock worth $42,406,693. Insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

BSX has been the subject of a number of recent analyst reports. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a research report on Wednesday, May 28th. Evercore ISI increased their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Leerink Partners initiated coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price on the stock. Finally, Barclays upped their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Twenty-two investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and a consensus target price of $116.09.

Boston Scientific Stock Performance

NYSE:BSX opened at $104.67 on Friday. Boston Scientific Corporation has a twelve month low of $71.88 and a twelve month high of $107.17. The stock has a market cap of $154.85 billion, a P/E ratio of 76.40, a PEG ratio of 2.70 and a beta of 0.68. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The business's 50-day moving average price is $102.51 and its two-hundred day moving average price is $99.44.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. Boston Scientific's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.56 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.